The profits of leading machinery companies are public: Medtronic, Mindray, Weigao, Abbott...

The outbreak of the new crown epidemic in 2020 has now entered its third year
.
In 2021, after the domestic epidemic is under control, the routine operation of hospitals will gradually recover, the operation of various projects has gradually entered the right track, and the operation of medical device enterprises will tend to be stable
.
Internationally, the epidemic has caused huge challenges to the medical and health systems of various countries.
Some European countries have begun to plan measures to make up for medical shortcomings, while the medical shortcomings exposed by the epidemic in developing countries are even more serious, and the demand for medical devices has increased.
big
.
The epidemic has put downward pressure on the global economy, especially in emerging markets with greater growth potential, which makes the cost-effectiveness of medical device products particularly important
.
In the post-epidemic era, what is the revenue and profit situation of leading companies in the domestic and international medical device markets? Top companies (in no particular order) In 2021, Mindray Medical's annual operating income will be 25.
27 billion yuan, a year-on-year increase of 20.
18%; the annual net profit attributable to shareholders of listed companies will be 8.
002 billion yuan, a year-on-year increase of 20.
19%
.
Among the three core businesses, the annual revenue of life information and support business is about 11.
15 billion yuan, an increase of 11.
47% year-on-year; the revenue of in vitro diagnostic products is 8.
449 billion yuan, a year-on-year increase of 27.
12%; the revenue of medical imaging business is about 5.
425 billion yuan , a year-on-year increase of 29.
29%
.
In addition, the company is actively promoting the four seed businesses of minimally invasive surgery, animal medicine, orthopedics and AED
.
Weigao’s revenue in 2021 will be about 13.
152 billion yuan, a year-on-year increase of 13.
2%; the net profit attributable to the company’s owners will be about 2.
245 billion yuan, a year-on-year increase of 7.
6%
.
Clinical nursing revenue was 4.
575 billion yuan, a year-on-year increase of 7.
2%; orthopedic product revenue was 2.
127 billion yuan, a year-on-year increase of 21.
7%; interventional product revenue was 1.
773 billion yuan, a year-on-year increase of 10.
01%; pharmaceutical packaging products were 2.
040 billion yuan, a year-on-year increase of 20.
5% ;Blood management products 977 million yuan, an increase of 19.
04% year-on-year
.
Dean Diagnostics achieved operating income of 13.
083 billion yuan in 2021, a year-on-year increase of 22.
85%; realized a net profit attributable to the parent of 1.
163 billion yuan, a year-on-year increase of 44.
83%
.
The total revenue of the diagnostic service business was 6.
620 billion yuan, a year-on-year increase of 30.
25%, of which the new crown nucleic acid detection revenue was 2.
606 billion yuan, and the diagnostic service business income after excluding the new crown nucleic acid detection revenue was 4.
014 billion yuan, a year-on-year increase of 31.
97%
.
After deducting the new crown nucleic acid detection business, the special inspection business (molecular diagnosis, pathological diagnosis and mass spectrometry) revenue achieved 1.
460 billion yuan, accounting for more than 40% of ICL's revenue, a year-on-year increase of 45.
85%
.
According to the 2021 annual performance report of Orient Bio, the total operating income during the reporting period was 10.
032 billion yuan, an increase of 207.
22% over the previous year; the net profit attributable to the owners of the parent company was 4.
777 billion yuan, an increase of 184.
80% over the previous year
.
Affected by the global COVID-19 epidemic, the sales performance of the novel coronavirus antigen rapid detection reagents (including home self-test) in the European market increased significantly during the reporting period, and the business of routine diagnostic reagents and diagnostic instruments developed
.
Steady Medical's 2021 operating income is 8.
037 billion yuan, a year-on-year decrease of 35.
87%; the net profit attributable to shareholders of listed companies is 1.
239 billion yuan, a year-on-year decrease of 67.
48%
.
Among them, the medical consumables business achieved sales revenue of 3.
922 billion yuan, a year-on-year decrease of 56.
03% and an increase of 160.
69% from 2019; the health consumer goods business achieved sales revenue of 4.
054 billion yuan, a year-on-year increase of 15.
27% compared to the same period in 2019.
An increase of 34.
79%
.
After excluding mask products of the same caliber, sales revenue increased by 24.
82% over the same period last year
.
BGI will achieve operating income of 6.
766 billion yuan in 2021, and net profit attributable to shareholders of listed companies of 1.
462 billion yuan
.
Reproductive health business now has an operating income of 1.
192 billion yuan; tumor prevention and control business achieved revenue of 380 million yuan, a year-on-year increase of 8.
12%; infection prevention and control business achieved revenue of 1.
158 billion yuan, a year-on-year increase of 73.
01%; multi-group big data and synthesis The field achieved revenue of 642 million yuan, a year-on-year increase of 2.
5%; the field of precision medical testing comprehensive solutions achieved revenue of 3.
382 billion yuan
.
Zhende Medical will achieve revenue of 5.
092 billion yuan in 2021, a year-on-year decrease of 51.
04%; net profit of 596 million yuan, a year-on-year decrease of 76.
63%
.
During the reporting period, the income of anti-epidemic-related infection control and protection products decreased by 76.
92%, while the income of non-anti-epidemic products maintained an increase.
Among them, the income of basic wound care increased by 15.
07%, the income of surgical infection control increased by 12.
51%, and the income of pressure therapy and fixed category increased by 15.
07%.
An increase of 40.
29%, stoma and modern wound care increased by 179.
58%
.
In 2021, Blue Sail Medical achieved operating income of 8.
109 billion yuan, a year-on-year increase of 3.
04%, and the net profit attributable to shareholders of listed companies was about 1.
156 billion yuan, a year-on-year decrease of 34.
28%
.
During the period, orders for various types of medical and protective gloves, masks, etc.
increased significantly.
The net profit of health protection products for the year was 2.
492 billion yuan; the cardiovascular and cerebrovascular business department lost 737 million yuan, and the coronary artery business was affected by the centralized procurement of stents and repeated overseas epidemics.
Large, the European market for the heart valve business is still in the early stage of development, domestic valve products have not yet been launched, and the research and development and clinical investment in valve and coronary products are still increasing
.
Daan Gene will achieve revenue of 7.
664 billion yuan in 2021, a year-on-year increase of 43.
49%, and net profit attributable to the parent of 3.
618 billion yuan, a year-on-year increase of 47.
74%
.
Among them, the revenue of the new coronavirus 2019-nCoV nucleic acid detection kit (fluorescent PCR method) was 4.
894 billion yuan, a year-on-year increase of 64.
48%, and the gross profit margin was 88.
65%, a year-on-year increase of 7.
96%
.
Yuyue Medical will achieve operating income of 6.
894 billion yuan in 2021, a year-on-year increase of 2.
51%; net profit of 1.
482 billion yuan, a year-on-year decrease of 15.
73%
.
In the respiratory therapy business, the revenue was 2.
623 billion yuan, a year-on-year increase of 16.
04%; the diabetes care business revenue was 457 million yuan, a year-on-year increase of 70.
1%; the infection control business revenue was 893 million yuan, a year-on-year decrease of 6.
03%; household electronic testing and in vitro diagnosis Revenue was 1.
448 billion yuan, a year-on-year decrease of 18.
11%; rehabilitation and clinical device revenue was 1.
228 billion yuan, a year-on-year increase of 13.
35%
.
Bloomage Bio's 2021 operating income was 4.
948 billion yuan, a year-on-year increase of 87.
93%, and a net profit of 782 million yuan, a year-on-year increase of 21.
13%
.
Among them, the raw material business achieved revenue of 905 million yuan, a year-on-year increase of 28.
62%; the medical terminal business achieved revenue of 700 million yuan, a year-on-year increase of 21.
54%, and the gross profit margin was 82.
05%
.
Among them, skin medical products achieved revenue of 504 million yuan, a year-on-year increase of 15.
88%; orthopedic injection products achieved revenue of 123 million yuan, a year-on-year increase of 37.
08%
.
MicroPort's 2021 annual revenue was US$779 million (approximately RMB 4.
955 billion), a year-on-year increase of 20%.
Excluding the impact of exchange rates, it would have increased by 15.
0% compared with the same period last year.
The company's equity shareholders accounted for a loss of US$276 million (compared to the same period last year as a loss of US$276 million).
$191 million)
.
Cardiovascular intervention is greatly affected by domestic centralized procurement.
In 2021, the global revenue of cardiovascular business is US$140 million, a year-on-year decrease of 10.
8%
.
The overseas revenue of orthopedic devices was US$193 million, an increase of 11.
8% year-on-year, and the domestic revenue was US$22 million, a year-on-year decrease of 31.
7%.
During the reporting period, the overall business loss narrowed by 57.
3%
.
Heart rate management business revenue was US$220 million, an increase of 18.
8% year-on-year
.
Revenue from the aortic and peripheral vascular intervention business was US$106 million, a year-on-year increase of 45.
6%
.
The heart valve business revenue was US$31 million, a year-on-year increase of 93.
2%
.
The robot business income was 2.
15 million yuan, mainly from the sales of the three-dimensional electronic laparoscope product Dragonfly Eye
.
Superstar Medical will realize a profit of 4.
931 billion yuan in 2021, a year-on-year increase of 20.
1%; the profit attributable to the owner of the parent company is about 3.
3 million yuan, and the loss in 2020 is about 591 million yuan
.
On April 8, Jidan announced that it plans to subscribe for the newly issued shares of Superstar Medical by paying in cash.
After the subscription is completed, it will become the controlling shareholder of the target company, and the target company will become the company's consolidated subsidiary
.
In 2021, Jidan will achieve revenue of 1.
372 billion yuan and net profit attributable to the parent of 392 million yuan
.
Shengxiang Bio will achieve revenue of 4.
515 billion yuan in 2021, a year-on-year decrease of 5.
22%; net profit attributable to shareholders of listed companies is 2.
243 billion yuan, a year-on-year decrease of 14.
29%; non-net profit deducted is 2.
151 billion yuan, a year-on-year decrease of 17.
05%
.
The revenue of diagnostic reagents was 3.
393 billion yuan, a year-on-year decrease of 12.
54%; the revenue of diagnostic instruments was 851 million yuan, a year-on-year increase of 30.
38%
.
Kehua Bio's 2021 annual performance report shows that during the reporting period, the company's operating income was about 4.
469 billion yuan, a year-on-year increase of 7.
55%; the net profit attributable to shareholders of the listed company was about 721 million yuan, a year-on-year increase of 6.
76%
.
Abbott reports fourth-quarter and full-year 2021 results
.
Net sales in the fourth quarter were US$11.
468 billion, a year-on-year increase of 7.
2%; net profit was US$1.
989 billion, compared with US$2.
162 billion in the same period last year
.
Divided by business, the revenue of the medical equipment business was US$3.
749 billion, a year-on-year increase of 15.
1%
.
Diagnostics business sales were $4.
471 billion, up 2.
9 percent year-on-year
.
Pharmaceutical business sales were $1.
203 billion, up 4.
9% year over year
.
Nutrition sales were $2.
043 billion, up 5.
5% year over year
.
Net sales in 2021 were $43.
075 billion, compared to $34.
608 billion in 2020
.
Net profit for the year was US$7.
071 billion, compared with US$4.
495 billion in the previous year
.
Danaher reports fourth quarter and full year 2021 results
.
Fourth-quarter sales were $8.
148 billion, compared with $6.
76 billion a year earlier
.
Net income for the quarter was $1.
747 billion, compared with $1.
2 billion a year earlier
.
Sales in 2021 were $29.
453 billion and $22.
284 billion in 2020
.
Net profit for the year was US$6.
269 billion, compared with US$3.
51 billion in the previous year
.
Medtronic announced financial results for the third quarter of fiscal 2022
.
Quarterly net sales were $7.
763 billion, compared with $7.
775 billion in the same period last year; net profit attributable to the company was $1.
48 billion, compared with $1.
27 billion in the same period last year, an increase of 16.
5% year-on-year
.
Divided by business, cardiovascular business revenue was $2.
745 billion, up 1% year-on-year; medical surgery business revenue was $2.
29 billion, down 1% year-on-year; neuroscience business revenue was $2.
144 billion, up 1% year-on-year; diabetes Operating revenue was $584 million, down 7% year over year
.
U.
S.
revenue was $3.
939 billion, accounting for 50.
8% of the company's revenue
.
Thermo Fisher Scientific reports fourth-quarter and full-year 2021 results
.
Fourth-quarter revenue was $10.
7 billion, compared with $10.
55 billion a year earlier
.
Net profit for the quarter was $1.
658 billion, compared with $2.
498 billion a year earlier
.
Among them, the life science business revenue was 4.
15 billion US dollars, a year-on-year increase of 38.
8%
.
Laboratory products and services revenue was $4.
195 billion, a year-on-year increase of 39.
2%
.
Professional diagnostic business revenue was US$1.
447 billion, a year-on-year increase of 13.
5%
.
Analytical instrument revenue was US$1.
725 billion, a year-on-year increase of US$16.
1%
.
Revenue in 2021 was $39.
211 billion, compared to $32.
218 billion in 2020
.
Net profit for the year was US$7.
725 billion, compared with US$6.
375 billion in the previous year
.
Fresenius SE & Co.
KGaA announces fourth quarter and full year 2021 results
.
Fourth-quarter sales were 9.
966 billion euros (about 10.
7 billion U.
S.
dollars), an increase of 7% over the same period last year
.
Net profit for the quarter was 521 million euros, up 5 percent from the same period a year earlier
.
Among them, the sales of Fresenius Medical Services were 4.
647 billion euros, a year-on-year increase of 6%
.
Sales of the Fresenius Kabi business were 1.
823 billion euros, flat year-on-year
.
Sales of the Fresenius Helios Clinic business were 2.
882 billion euros, an increase of 9% year-on-year
.
Fresenius VAMED's sales were 748 million euros, an increase of 30% year-on-year
.
Group sales in 2021 will be 37.
52 billion euros, a year-on-year increase of 3%
.
The net profit for the year was 1.
867 billion euros, a year-on-year increase of 4%
.
Johnson & Johnson announces fourth quarter and full year 2021 financial results
.
In the fourth quarter, sales were US$24.
804 billion, an increase of 10.
4% over the same period last year; net profit was US$4.
736 billion, an increase of 172.
5% over the same period last year
.
By business, sales of the medical device business in the fourth quarter were US$6.
859 billion, a year-on-year increase of 4.
1%
.
In 2021, Johnson & Johnson's total sales will be US$93.
775 billion, a year-on-year increase of 13.
6%; net profit will be US$20.
878 billion, a year-on-year increase of 41.
9%
.
Siemens Healthineers announced results for the first quarter of fiscal 2022 (October-December 2021)
.
Quarterly revenue of EUR 5.
068 billion (approximately USD 5.
46 billion), compared to EUR 3.
868 billion in the same period last year
.
Among them, Varian contributed 750 million euros in revenue, and the new coronavirus antigen rapid detection business contributed 329 million euros in revenue
.
Net profit for the quarter was 472 million euros, compared with 437 million euros in the same period last year
.
Philips announced that net sales in the fourth quarter of 2021 were 4.
944 billion euros (about 5.
23 billion U.
S.
dollars), compared with 5.
235 billion euros in the same period last year; net profit was 151 million euros, compared with 607 million euros in the same period last year, a decrease of 75% year-on-year %
.
Divided by business, the sales of the diagnosis and treatment business were 2.
508 billion euros, the sales of the connected care business were 1.
205 billion euros, the sales of the personal health business were 1.
045 billion euros, and the sales of other businesses were 186 million euros
.
Philips' net sales in 2021 will be 17.
156 billion euros and 17.
313 billion euros in 2020; net profit will be 3.
323 billion euros and 1.
195 billion euros in 2020
.
BD (BD) announces results for the first quarter of the fiscal year ended December 31, 2021
.
Quarterly revenue was $4.
995 billion, compared to $5.
315 billion a year earlier
.
Quarterly net profit was $655 million, compared with $981 million a year earlier
.
Medical device and equipment maker Stryker announced fourth-quarter and full-year 2021 results
.
Net sales in the fourth quarter were $4.
7 billion, compared with $4.
262 billion in the same period last year
.
Net income for the quarter was $662 million, compared with $568 million a year earlier
.
Net sales in 2021 were $17.
108 billion, compared to $14.
351 billion in 2020
.
Net profit for the year was US$1.
994 billion, compared with US$1.
599 billion in the previous year
.
General Electric (GE) announces fourth-quarter and full-year 2021 results
.
Total fourth-quarter revenue was $20.
303 billion, down 3% year over year
.
Among them, the organic revenue of the industrial sector was $19.
6 billion, down 3% year-on-year
.
Net loss attributable to common shareholders of the company was US$3.
900 billion, compared to a net profit of US$2.
442 billion in the same period last year
.
By business, healthcare revenue was $4.
625 billion, down 4% year over year
.
Roche reported results for 2021, with full-year sales of CHF 62.
8 billion, compared to CHF 58.
3 billion a year earlier
.
Net profit was CHF 14.
9 billion, compared with CHF 15.
1 billion in the same period last year; core operating profit was CHF 21.
9 billion
.
Among them, the diagnostic business sales were 17.
8 billion Swiss francs (about 18.
8 billion US dollars), compared with 13.
8 billion Swiss francs in the previous year
.
Baxter International Inc announces fourth quarter and full year 2021 results
.
Fourth quarter net sales were $3.
514 billion, compared to $3.
181 billion in the same period last year
.
Net income for the quarter was $238 million, compared with $168 million a year earlier
.
Net sales in 2021 were $12.
784 billion, compared to $11.
673 billion in 2020
.
Net profit for the year was US$1.
284 billion, compared with US$1.
102 billion in the previous year
.
Henry Schein reports fourth quarter and full year 2021 results
.
Net sales in the fourth quarter were $3.
331 billion, compared to $3.
166 billion in the same period last year
.
Net income for the quarter was $147 million, compared with $143 million a year earlier
.
Net sales of $12.
4 billion in 2021 and $10.
12 billion in 2020
.
Net profit for the year was US$631 million, compared with US$404 million in the previous year
.
Boston Scientific announces fourth quarter and full year 2021 results
.
Fourth-quarter net sales of $3.
127 billion compared to $2.
708 billion in the same period last year
.
Net income for the quarter was $80 million, compared with $196 million a year earlier
.
Net sales of $11.
888 billion in 2021 and $9.
913 billion in 2020
.
Net profit for the year was US$985 million, compared with a net loss of US$115 million in the previous year
.
Owens & Minor announces fourth quarter and full year 2021 results
.
Net revenue for the fourth quarter was $2.
467 billion, compared to $2.
362 billion a year earlier
.
Net profit for the quarter was $41.
98 million, compared with $50.
74 million in the same period last year
.
Net revenue in 2021 was $9.
785 billion, compared to $8.
48 billion in 2020
.
Net profit for the year was US$221 million, compared with US$29.
87 million in the previous year
.
3M Company reports fourth quarter and full year 2021 results
.
Net sales in the fourth quarter were $8.
612 billion and net profit for the quarter was $1.
339 billion
.
Net sales in 2021 will be US$35.
355 billion, and annual net profit will be US$5.
921 billion
.
Among them, the net sales of health care products in the fourth quarter were 2.
306 billion US dollars, and the full year was 8.
445 billion US dollars
.
Alcon reports fourth-quarter and full-year 2021 results
.
Fourth-quarter revenue was $2.
149 billion, compared with $1.
94 billion in the same period last year
.
Net income for the quarter was $139 million, compared with $95 million a year earlier
.
Revenue in 2021 was $8.
291 billion, compared to $6.
833 billion in 2020
.
Net profit for the year was US$376 million, compared with a net loss of US$5.
31 in the previous year
.
Zimmer Biomet Holdings Inc announced fourth quarter and full year 2021 results
.
Fourth quarter net sales of $2,038 million, compared to $2,085 million in the same period last year
.
Net loss for the quarter was $84 million, compared with a net profit of $334 million a year earlier
.
Net sales in 2021 were $7.
836 billion, compared to $7.
024 billion in 2020
.
Net profit for the year was US$402 million, compared with a net loss of US$139 million in the previous year
.
Olympus (OLYMPUS) reports results for the first nine months of the fiscal year ended December 31, 2021
.
The current revenue was 629.
757 billion yen (about 4.
93 billion US dollars), compared with 513.
584 billion yen in the same period last year
.
Operating profit for the period was 108.
91 billion yen, compared with 64.
734 billion yen in the same period last year
.
Net profit for the period was 87.
667 billion yen, compared with 1.
624 billion yen in the same period last year
.
Terumo reports results for the first nine months of the fiscal year ended December 31, 2021
.
The current revenue was 523.
482 billion yen (about 4.
094 billion US dollars), compared with 448.
628 billion yen in the same period last year
.
Operating profit for the period was 94.
455 billion yen, compared to 75.
272 billion yen in the same period last year
.
Net profit for the period was 71.
696 billion yen, compared with 58.
601 billion yen in the same period last year
.
Canon Group (Canon) released its 2021 financial report
.
In 2021, the group's turnover will increase by 11.
2% year-on-year to 3,513.
357 billion yen, and the net profit will increase by 157.
7%
.
Among them, the medical business turnover increased by 10.
2% to 480.
4 billion yen (about 3.
76 billion US dollars)
.